Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II of Randomized, Double-blind, Placebo-controlled, Multi-center Study of Hepalatide for Injection Combined With Pegylated Interferon and TAF as Finite Treatment in Chronic Hepatitis B Patients

NCT05244057 is registered in ClinicalTrials.gov with Shanghai HEP Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT05244057
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05244057 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II of Randomized, Double-blind, Placebo-controlled, Multi-center Study of Hepalatide for Injection Combined With Pegylated Interferon and TAF as Finite Treatment in Chronic Hepatitis B Patients
Lead sponsor
Shanghai HEP Pharmaceutical Co., Ltd.
Phase
Phase 2
Overall status
Completed
Start date
August 23, 2022
Completion date
June 24, 2024
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis b